

## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

T. Horinouchi reports the following:

Employer: Kobe University Graduate School of Medicine; and Research Funding: Otsuka Pharmaceutical Co., Ltd.; Sysmex Corporation, Zenyakukogyo Co., Ltd.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Tomoko Horinouchi

Manuscript ID: K360-2024-000303R1

Manuscript Title: Clinical, Pathological, and Genetic Characteristics of Patients with Digenic Alport Syndrome

Date of Completion: July 31, 2024

Disclosure Updated Date: May 6, 2024

## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

Y. Ichikawa reports the following:

Employer: Department of Pediatrics, Kobe University Graduate School of Medicine

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Yuta Ichikawa

Manuscript ID: K360-2024-000303R1

Manuscript Title: Clinical, Pathological, and Genetic Characteristics of Patients with Digenic Alport Syndrome

Date of Completion: July 31, 2024

Disclosure Updated Date: July 31, 2024

## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

Y. Inoki reports the following:

Employer: Kobe university

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Yuta Inoki

Manuscript ID: K360-2024-000303R1

Manuscript Title: Clinical, Pathological, and Genetic Characteristics of Patients with Digenic Alport Syndrome

Date of Completion: July 31, 2024

Disclosure Updated Date: May 9, 2024

## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

S. Ishimori reports the following:

Employer: Kobe University Graduate School of Medicine

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Shingo Ishimori

Manuscript ID: K360-2024-000303R1

Manuscript Title: Clinical, Pathological, and Genetic Characteristics of Patients with Digenic Alport Syndrome,

Date of Completion: July 31, 2024

Disclosure Updated Date: July 31, 2024

## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

H. Kitakado reports the following:

Employer: Kobe University Graduate School of Medicine

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Hideaki Kitakado

Manuscript ID: K360-2024-000303R1

Manuscript Title: Clinical, Pathological, and Genetic Characteristics of Patients with Digenic Alport Syndrome

Date of Completion: July 31, 2024

Disclosure Updated Date: May 1, 2024

## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

A. Kondo reports the following:

Employer: Kobe University Graduate School of Medicine

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Atsushi Kondo

Manuscript ID: K360-2024-000303R1

Manuscript Title: Clinical, Pathological, and Genetic Characteristics of Patients with Digenic Alport Syndrome

Date of Completion: August 5, 2024

Disclosure Updated Date: August 5, 2024

## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

C. Nagano has nothing to disclose.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: China Nagano

Manuscript ID: K360-2024-000303R1

Manuscript Title: Clinical, Pathological, and Genetic Characteristics of Patients with Digenic Alport Syndrome

Date of Completion: July 31, 2024

Disclosure Updated Date: May 1, 2024

## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

K. Nozu reports the following:

Employer: Kobe University; Research Funding: Shionogi Inc., Chugai Pharmaceutical Company, Kyowa Kirin Pharmaceutical Company, Dainippon Sumitomo Pharmaceutical Company. Zenyaku Kogyo Pharmaceutical Company; Honoraria: Ono Pharma, Astellas Pharma, Novo Nordisk Pharma, Alexion Pharma, Sumitomo Pharma, Sanofi, Otsuka Pharma, Daiichi Sankyo, Miyarisan.; Patents or Royalties: Kandai Nozu has a patent for developing exon skipping therapy for Alport syndrome patients.; Advisory or Leadership Role: Kyowa Kirin Co. Ltd., Toa Eiyo LTD., and Taisho Pharmaceutical Co. Ltd.; and Speakers Bureau: I receive lecture fees from pharmaceutical companies listed bellow.; 1. Sumitomo Dainippon Pharma Co., Ltd. ; 2. DAIICHI SANKYO COMPANY, LIMITED.; 3. Novartis pharma Co. Ltd.; 4. Chugai Pharmaceutical Co., Ltd. 5. Chugai Pharmaceutical Company, 6. Kyowa Kirin Pharmaceutical Company.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Kandai Nozu

Manuscript ID: K360-2024-000303

Manuscript Title: Clinical, Pathological, and Genetic Characteristics of Patients with Digenic Alport Syndrome

Date of Completion: July 31, 2024

Disclosure Updated Date: July 31, 2024



## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

N. Sakakibara reports the following:  
Employer: KOBE UNIVERSITY

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Nana Sakakibara

Manuscript ID: K360-2024-000303R1

Manuscript Title: Clinical, Pathological, and Genetic Characteristics of Patients with Digenic Alport Syndrome

Date of Completion: August 3, 2024

Disclosure Updated Date: August 3, 2024

## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

Y. Tanaka reports the following:

Employer: kobe university

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Yu Tanaka

Manuscript ID: K360-2024-000303R1

Manuscript Title: Clinical, Pathological, and Genetic Characteristics of Patients with Digenic Alport Syndrome.

Date of Completion: July 31, 2024

Disclosure Updated Date: July 31, 2024

## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

C. Ueda reports the following:

Employer: Kobe University Graduate School of Medicine

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Chika Ueda

Manuscript ID: K360-2024-000303R1

Manuscript Title: Clinical, Pathological, and Genetic Characteristics of Patients with Digenic Alport Syndrome

Date of Completion: July 31, 2024

Disclosure Updated Date: May 1, 2024

## ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

T. Yamamura reports the following:

Employer: Kobe University Graduate School of Medicine

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Tomohiko Yamamura

Manuscript ID: K360-2024-000303R1

Manuscript Title: "Clinical, Pathological, and Genetic Characteristics of Patients with Digenic Alport Syndrome"

Date of Completion: July 31, 2024

Disclosure Updated Date: May 1, 2024